BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeeneldin AA, Salem SE, Tabashy RH, Ibrahim AA, Alieldin NH. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients. J Egypt Natl Canc Inst 2013;25:143-50. [PMID: 23932751 DOI: 10.1016/j.jnci.2013.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Zeeneldin AA, Salem SE, Darwish AD, El-Gammal MM, Hussein MM, Saadeldin M. Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors. J Hepatocell Carcinoma 2015;2:3-9. [PMID: 27508189 DOI: 10.2147/JHC.S73828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
2 Haffez H, Taha H, Farrag NS, Amin AM, Hassan ZA. Biological Screening and Radiolabeling of Raptinal as a Potential Anticancer Novel Drug in Hepatocellular Carcinoma Model. European Journal of Pharmaceutical Sciences 2021;158:105653. [DOI: 10.1016/j.ejps.2020.105653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Eltabbakh M, Abdella HM, Askar S, Abuhashima MA, Shaker MK. Risk stratification of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization using an alpha-fetoprotein model. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00155-y] [Reference Citation Analysis]
4 Wang CY, Li S. Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: A single center 14 years experience from China. Medicine (Baltimore) 2019;98:e14070. [PMID: 30681563 DOI: 10.1097/MD.0000000000014070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
5 Wu J, Li A, Yang J, Lu Y, Li J. Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study. Onco Targets Ther 2017;10:2761-8. [PMID: 28603426 DOI: 10.2147/OTT.S131022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
6 Ali HEA, Emam AA, Zeeneldin AA, Srour R, Tabashy R, El-Desouky ED, Abd Elmageed ZY, Abdel-Wahab AA. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization. Clin Biochem 2019;65:45-52. [PMID: 30653948 DOI: 10.1016/j.clinbiochem.2019.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
7 El Mahdy Korah T, Abd Elfatah Badr E, Mohamed Emara M, Ahmed Samy Kohla M, Gamal Saad Michael G. Relation between sex hormones and hepatocellular carcinoma. Andrologia 2016;48:948-55. [PMID: 26791111 DOI: 10.1111/and.12536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
8 El-Halawany MS, Ismail HM, Zeeneldin AA, Elfiky A, Tantawy M, Kobaisi MH, Hamed I, Abdel Wahab AH. Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment. Biomed Res Int 2015;2015:649750. [PMID: 25811030 DOI: 10.1155/2015/649750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]